The role of oxidized phospholipids in atherosclerosis

This publication has 48 references indexed in Scilit:

• Dyslipidemia inhibits Toll-like receptor–induced activation of CD8α-negative dendritic cells and protective Th1 type immunity
  The Journal of Experimental Medicine, 2007
• Vascular Endothelial Growth Factor Receptor 2 Plays a Role in the Activation of Aortic Endothelial Cells by Oxidized Phospholipids
  Arteriosclerosis, Thrombosis, and Vascular Biology, 2007
• Lipoprotein(a): A Unique Risk Factor for Cardiovascular Disease
  Clinics In Laboratory Medicine, 2006
• Epoxycyclopentenone-Containing Oxidized Phospholipids Restore Endothelial Barrier Function via Cdc42 and Rac
  Circulation Research, 2004
• Dyslipidemia Associated with Atherosclerotic Disease Systemically Alters Dendritic Cell Mobilization
  Immunity, 2004
• Specific Phospholipid Oxidation Products Inhibit Ligand Activation of Toll-Like Receptors 4 and 2
  Arteriosclerosis, Thrombosis, and Vascular Biology, 2003
• Reduced Connexin43 Expression Inhibits Atherosclerotic Lesion Formation in Low-Density Lipoprotein Receptor–Deficient Mice
  Circulation, 2003
• Minimally Modified LDL Binds to CD14, Induces Macrophage Spreading via TLR4/MD-2, and Inhibits Phagocytosis of Apoptotic Cells
  Journal of Biological Chemistry, 2003
• Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells.
  Journal of Clinical Investigation, 1995
• Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids.
  Proceedings of the National Academy of Sciences, 1992